Trial Profile

Characteristics and Real-world Outcomes of Patients Administered with Fecal Microbiota, live-jslm for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Oct 2025 According to Ferring Pharmaceuticals media release, data for patients aged >/= 18 years with rCDI (n=128) who received REBYOTA in physician offices between February 2023 and March 2025 of which 75% (n=96) achieved treatment success (defined as no CDI recurrence) at 8 weeks, were presented at IDWeek 2025 (presentation number 352).
20 Oct 2025 Results presented in the Ferring Pharmaceuticals Media Release.
02 Jun 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com